CN1706371A - A kind of efficient irinatin preparation and preparation method thereof - Google Patents
A kind of efficient irinatin preparation and preparation method thereof Download PDFInfo
- Publication number
- CN1706371A CN1706371A CN 200510046524 CN200510046524A CN1706371A CN 1706371 A CN1706371 A CN 1706371A CN 200510046524 CN200510046524 CN 200510046524 CN 200510046524 A CN200510046524 A CN 200510046524A CN 1706371 A CN1706371 A CN 1706371A
- Authority
- CN
- China
- Prior art keywords
- preparation
- acid
- oil
- medicine
- irisquinonum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 68
- 239000003814 drug Substances 0.000 claims abstract description 46
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 37
- 239000000839 emulsion Substances 0.000 claims abstract description 31
- 238000002347 injection Methods 0.000 claims abstract description 30
- 239000007924 injection Substances 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- 238000004108 freeze drying Methods 0.000 claims abstract description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 18
- 239000002502 liposome Substances 0.000 claims abstract description 18
- 239000002245 particle Substances 0.000 claims abstract description 16
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 11
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 9
- 235000003599 food sweetener Nutrition 0.000 claims abstract 3
- 239000003755 preservative agent Substances 0.000 claims abstract 3
- 239000003765 sweetening agent Substances 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 62
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 30
- 239000003921 oil Substances 0.000 claims description 27
- 235000019198 oils Nutrition 0.000 claims description 27
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 22
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 22
- 235000011187 glycerol Nutrition 0.000 claims description 21
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 19
- 239000002105 nanoparticle Substances 0.000 claims description 17
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 15
- 238000001694 spray drying Methods 0.000 claims description 14
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- 239000012071 phase Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 9
- 229930195725 Mannitol Natural products 0.000 claims description 9
- 229930003427 Vitamin E Natural products 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 9
- 239000000594 mannitol Substances 0.000 claims description 9
- 235000010355 mannitol Nutrition 0.000 claims description 9
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 9
- 229940083466 soybean lecithin Drugs 0.000 claims description 9
- 235000019165 vitamin E Nutrition 0.000 claims description 9
- 239000011709 vitamin E Substances 0.000 claims description 9
- 229940046009 vitamin E Drugs 0.000 claims description 9
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 8
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 8
- -1 Diol succinate Chemical class 0.000 claims description 8
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 210000003022 colostrum Anatomy 0.000 claims description 8
- 235000021277 colostrum Nutrition 0.000 claims description 8
- 235000019136 lipoic acid Nutrition 0.000 claims description 8
- 229940042880 natural phospholipid Drugs 0.000 claims description 8
- 239000003549 soybean oil Substances 0.000 claims description 8
- 235000012424 soybean oil Nutrition 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 229960002663 thioctic acid Drugs 0.000 claims description 8
- 239000008158 vegetable oil Substances 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 6
- 239000007957 coemulsifier Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical group OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims description 5
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000004006 olive oil Substances 0.000 claims description 5
- 235000008390 olive oil Nutrition 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 239000005642 Oleic acid Substances 0.000 claims description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 4
- 235000019485 Safflower oil Nutrition 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- BPHQZTVXXXJVHI-UHFFFAOYSA-N dimyristoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-UHFFFAOYSA-N 0.000 claims description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 235000005713 safflower oil Nutrition 0.000 claims description 4
- 239000003813 safflower oil Substances 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 3
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 claims description 3
- 244000060011 Cocos nucifera Species 0.000 claims description 3
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 3
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 3
- 229960003964 deoxycholic acid Drugs 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 3
- 229940093471 ethyl oleate Drugs 0.000 claims description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 3
- 229920001992 poloxamer 407 Polymers 0.000 claims description 3
- 229940044476 poloxamer 407 Drugs 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 2
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 244000099147 Ananas comosus Species 0.000 claims description 2
- 235000007119 Ananas comosus Nutrition 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 239000004380 Cholic acid Substances 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 239000005639 Lauric acid Substances 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 claims description 2
- 239000010775 animal oil Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 2
- 235000019416 cholic acid Nutrition 0.000 claims description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 2
- 229960002471 cholic acid Drugs 0.000 claims description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 2
- 229960002997 dehydrocholic acid Drugs 0.000 claims description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 235000021313 oleic acid Nutrition 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 239000003223 protective agent Substances 0.000 claims description 2
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 3
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 claims 2
- IJFVSSZAOYLHEE-SSEXGKCCSA-N 1,2-dilauroyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-N 0.000 claims 2
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 claims 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 2
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 claims 2
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 claims 2
- 101001000212 Rattus norvegicus Decorin Proteins 0.000 claims 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 2
- 239000003240 coconut oil Substances 0.000 claims 2
- 235000019864 coconut oil Nutrition 0.000 claims 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 2
- LHCZDUCPSRJDJT-UHFFFAOYSA-N dilauroyl phosphatidylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCC LHCZDUCPSRJDJT-UHFFFAOYSA-N 0.000 claims 2
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 claims 2
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 claims 2
- FVJZSBGHRPJMMA-UHFFFAOYSA-N distearoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-UHFFFAOYSA-N 0.000 claims 2
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 claims 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 2
- 229940039673 echinacea preparation Drugs 0.000 claims 2
- 238000000265 homogenisation Methods 0.000 claims 2
- 229940099578 hydrogenated soybean lecithin Drugs 0.000 claims 2
- 229960002446 octanoic acid Drugs 0.000 claims 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims 2
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 1
- 229940114069 12-hydroxystearate Drugs 0.000 claims 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- WPQRDUGBKUNFJW-SLUROAMNSA-N Apigenin 7-(6''-p-coumarylglucoside) Natural products O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4ccc(O)cc4)Oc3c2)O1)/C=C/c1ccc(O)cc1 WPQRDUGBKUNFJW-SLUROAMNSA-N 0.000 claims 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 claims 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 claims 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 claims 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 1
- WPQRDUGBKUNFJW-ZZSHFKPLSA-N [(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-[5-hydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxyoxan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound C([C@@H]1[C@H]([C@@H]([C@@H](O)[C@H](OC=2C=C3C(C(C=C(O3)C=3C=CC(O)=CC=3)=O)=C(O)C=2)O1)O)O)OC(=O)\C=C\C1=CC=C(O)C=C1 WPQRDUGBKUNFJW-ZZSHFKPLSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 1
- 239000009050 echinacin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 229940087068 glyceryl caprylate Drugs 0.000 claims 1
- 239000011261 inert gas Substances 0.000 claims 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims 1
- 239000012982 microporous membrane Substances 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- 239000007968 orange flavor Substances 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims 1
- 235000019204 saccharin Nutrition 0.000 claims 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 1
- 229940081974 saccharin Drugs 0.000 claims 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 235000003441 saturated fatty acids Nutrition 0.000 claims 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims 1
- 235000010265 sodium sulphite Nutrition 0.000 claims 1
- 229960004793 sucrose Drugs 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 abstract description 23
- 238000012856 packing Methods 0.000 abstract description 14
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 7
- 238000001914 filtration Methods 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 238000013329 compounding Methods 0.000 abstract 2
- 239000000686 essence Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 239000007921 spray Substances 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 238000005516 engineering process Methods 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 238000005303 weighing Methods 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 238000001959 radiotherapy Methods 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 8
- 239000000787 lecithin Substances 0.000 description 8
- 235000010445 lecithin Nutrition 0.000 description 8
- 229940067606 lecithin Drugs 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000008215 water for injection Substances 0.000 description 7
- 102000002322 Egg Proteins Human genes 0.000 description 6
- 108010000912 Egg Proteins Proteins 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 6
- 125000005456 glyceride group Chemical group 0.000 description 6
- 210000004681 ovum Anatomy 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229940087168 alpha tocopherol Drugs 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 4
- 229960000984 tocofersolan Drugs 0.000 description 4
- 239000002076 α-tocopherol Substances 0.000 description 4
- 235000004835 α-tocopherol Nutrition 0.000 description 4
- YYCCUFKHCNSRIA-HJWRWDBZSA-N 2-[(z)-heptadec-10-enyl]-6-methoxycyclohexa-2,5-diene-1,4-dione Chemical compound CCCCCC\C=C/CCCCCCCCCC1=CC(=O)C=C(OC)C1=O YYCCUFKHCNSRIA-HJWRWDBZSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 3
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- YYCCUFKHCNSRIA-UHFFFAOYSA-N Pallasone A Natural products CCCCCCC=CCCCCCCCCCC1=CC(=O)C=C(OC)C1=O YYCCUFKHCNSRIA-UHFFFAOYSA-N 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 201000005619 esophageal carcinoma Diseases 0.000 description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 3
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 2
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 2
- 244000147568 Laurus nobilis Species 0.000 description 2
- 235000017858 Laurus nobilis Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229940072106 hydroxystearate Drugs 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 description 2
- 229940067626 phosphatidylinositols Drugs 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000002534 radiation-sensitizing agent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 150000003900 succinic acid esters Chemical class 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 229940005561 1,4-benzoquinone Drugs 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100001048 fetal toxicity Toxicity 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000000637 radiosensitizating effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000188 sister chromatid exchange Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 108010013480 succinylated gelatin Proteins 0.000 description 1
- 229940007079 succinylated gelatin Drugs 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 231100000462 teratogen Toxicity 0.000 description 1
- 239000003439 teratogenic agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention is efficient sword-like iris seed preparation and its preparation process. The sword-like iris seed preparation may be liposome, emulsifier, nanometer particle or spray dried or freeze dried powder for orally taking or injection, and may have pharmaceutically acceptable preservative, sweetener and essence. The liposome consists of medicine, phospholipid and cholesterol in the weight ratio of 1 to 5-100 to 0-50, and has pH value of 4-8 and granularity of 5-5000 nm. The preparation process includes: 1. preparing oil phase in compounding tank, 2. preparing water phase in compounding tank, 3. adding water phase into oil phase to form initial emulsion, 4. suction filtering the initial emulsion in G3 funnel, regulating pH value to 3-9, and 5. processing in homogenizer, freeze drying and packing as emulsion. The preparation process of the present invention has fast and effective absorption and high blood medicine concentration.
Description
Technical field:
The present invention relates to medical technical field, exactly it is a kind of sword-like iris seed preparation and preparation method thereof efficiently.
Background technology:
The chemical name of Irisquinonum is: irisquinone, 6-methoxyl group-2-Δ
10 '-along 17 alkene-1,4-benzoquinone.But also contain the part dihydroirisquinone, pallason B.
Its structural formula is:
Irisquinone
Molecular formula: C
24H
38O
3
Molecular weight: 374.56
Dihydroirisquinone, pallason B
Molecular formula: C
24H
40O
3
Molecular weight: 376.58
The pharmacological action of Irisquinonum: be radiosensitizer, the growth of cell strain, tumor animal tumor and anoxic cells such as human cervical carcinoma, mice ehrlich ascites tumor, mouse lymphocyte leukemia is had radiosensitizing effect.Its mechanism of action is: suppress malignant cell and breathe, reduce oxygen consumption; Selectivity reduces malignant cell glutathion inside content; Suppress the synthetic and post-rift reparation of malignant cell DNA; Retardance malignant cell growth cycle is in to the ray sensitive G
1Phase.Acute toxicity: Irisquinonum is once irritated stomach LD
50Be 2590.6mg/kg; Mice once abdominal cavity injection LD
50Be 35.06 ± 0.99mg/kg.The animal poisoning symptom is hair pine, anorexia, loose stool, the visible flatulence of postmortem.Long term toxicity: 1. irritate stomach every day and give rat Irisquinonum 62.5,125,250mg/kg three months, the result shows liver function outer (SGPT slightly Irisquinonum raises), and hemogram and other main biochemical indicator do not have obvious change.2. irritate stomach every day and give Canis familiaris L. Irisquinonum 30mg/kg, 60mg/kg two months, the result shows that main organs do not see the substance damage that causes because of medicine.Main toxicity is gastrointestinal reaction, and this reaction prolongs or reduce dosage in time and recovery voluntarily.Tertogenicity test: the result shows continuous 10 days of the oral Irisquinonum 300mg/kg of pregnant Mus, can cause 25% animal dead, and can cause serious fetal toxicity reaction, makes most of pregnant Mus miscarry, absorb tire in early days, but tire Os Mus bone internal organs are not caused deformity; 60mg/kg treated animal filling stomach did not have obvious poisoning symptom in 10 days except that part animal perineum place secretions increase, symptom disappears automatically after the drug withdrawal, and skeleton of tire Mus and internal organs all do not cause deformity, show that Irisquinonum is non-teratogen.Mutagenicity test: microorganism reverse mutation test, sister chromatid exchange test, micronucleus test show that Irisquinonum is non-mutagen.Its plasma concentration is two chambers model, t after the oral this product of mice with tumor
1/2 αBe 0.096 hour, t
1/2 βBe 73.72 hours, Vd is 0.150L, shows that this product infiltration rate is fast, and the elimination time is long; The tissue distribution situation shows that medicine holdup time in digestive tract is long, and the tumor body radioactivity was the highest in 12 hours, and blood drug level still maintained this level in 24 hours, also has in lung and the thymus than high radioactivity, and brain and muscle are minimum.Behind this product single administration, existing than high radioactivity in the urine after half an hour, the discharge rate after 24 hours in excrement and the urine is respectively 14.8% and 30.3%.This product is a radiosensitizer, is used for the radiotherapy of radiocurable pulmonary carcinoma, esophageal carcinoma and incidence cancer etc.Oral meal, 2 times on the one, one time 2, take respectively at radiotherapy is forward and backward.Children's is cut down according to the circumstance.This product should begin to take before accepting radiotherapy 2-3 day, takes continuously until radiotherapy and finishes.Untoward reaction: part patient has slight gastrointestinal reaction, and as nausea,vomiting,diarrhea etc., its incidence rate height during than radiotherapy alone does not generally influence the continuation medication, reacts the patient individually, but decrement or symptomatic treatment, and one after each meal can reduce the reaction of stomach.Existing dosage form is capsule 55mg (in irisquinone and a dihydroirisquinone, pallason B total amount)
Irisquinonum is indissoluble in water, the while less stable, in order to improve dissolubility and stability in the water, there is the author to be made into cyclodextrin inclusion complex (the beta-schardinger dextrin-inclusion complex research Acta Pharmaceutica Sinica of cancer therapy drug Irisquinonum: 2002,37 (12): 963~966).In addition, because Irisquinonum indissoluble in water, its oral absorption is few (can be from irritating stomach LD
502590.6mg/kg; Mice once abdominal cavity injection LD
50Be 35.06 ± 0.99mg/kg, differ 70 surplus times) and individual variation big.For the injection feasibility is described, there is research worker to measure apparent pharmacokinetic parameters with chmice acute cumulative mortality method, the result shows that the apparent pharmacokinetic parameters of ip route of administration is similar to the gastric infusion approach, therefore taking drug administration by injection is feasible (the research Tianjin pharmacy 2002,14 (3) of the chmice acute cumulative mortality method mensuration apparent pharmacokinetic parameters of Irisquinonum: 36~37).
Irisquinonum is widely used (the Chinese clinical tumor of the perspective study of Irisquinonum radiation sensitization (attached 120 routine clinical analysis): 2003,30 (5): 328~330 in clinical; Irisquinonum is to anti-cisplatin Lu-csf-1 ADDP549 drug resistance inversion and possible machine-processed Chinese Medical Journal 2001,81 (22): 1392~1393; The clinical research Nanjing Medical University journal (natural science edition) 2001,21 (4): 328~330 of Irisquinonum sensitization in nasopharyngeal carcinoma radiotherapy; Treatment middle and advanced stage nasopharyngeal carcinoma efficacy analysis China clinical tumor 2001,28 (6): 439~440 is share in Irisquinonum and radiotherapy; Irisquinonum radiation sensitization treatment curative effect of esophageal carcinoma is observed Journal of Clinical Oncology: 2000,5 (4): 272~274; Irisquinonum influences Zhongshan Medical Univ.'s journal to 153SmEDTMP treatment nasopharyngeal carcinoma metastatic tumor of bone: 1998,19 (2): 142~143,149), and clinical effectiveness is remarkable, and effective percentage brings up to 62.5% by 10% during as therapeutic alliance; During the radiotherapy full dose, the tumor rate that disappears entirely brings up to 80% by 40%, and (the Irisquinonum capsule merges the Chinese clinical tumor of radiotherapy 62 routine esophageal carcinoma clinical observations: 1999,26 (8): 639~640), primary tumor and metastasis effective percentage, by 78.6%, 70.0% brings up to 94.3%, 87.5%, and (peace stuck glue capsule merges the Chinese clinical tumor 1999,26 (7) of radiotherapy malignant tumor 140 routine phase clinical observations: 547~548).
Blood albumin has important physiological function in blood, the normal osmotic pressure of blood is relevant with keeping, and is the main adjusting material of blood total osmotic pressure, lacks this albumin and may cause the body edema.Another effect of human albumin is to transport fatty acid as the carrier participation of fatty acid.Can utilize the human albumin as pharmaceutical carrier, the preparation nanometer formulation.
Summary of the invention:
But the objective of the invention is to prepare the preparation method of a kind of sword-like iris seed preparation efficiently and industrial applications thereof.Said efficient sword-like iris seed preparation comprises " liposome ", " Emulsion ", " nanoparticle ", and spray drying or lyophilized powder, prepared preparation can oral (antiseptic, sweeting agent, the essence that can add as required, the medicament allowed band) or drug administration by injection.Said antiseptic (antibacterial) is benzyl alcohol, benzoic acid (and salt), sorbic acid (and salt), parabens.Sweeting agent is sucrose, glucide, aspartame, protein sugar etc.; Essence is cream flavour, Fructus Citri tangerinae essence, cocoanut flavour, flavoring pineapple essence etc.Said lipid system is made up of medicine and phospholipid, cholesterol, and the ratio that medicine and phospholipid, cholesterol are formed is: 1: 5-100: 0-50 (W/W/W), its pH scope is: 4-8 (the medicine indissoluble is separated in this scope), particle size range is 10nm-5000nm.Said phospholipid is that PC (phosphatidylcholine) content is greater than 40% natural phospholipid, semi-synthetic phospholipid or synthetic phospholipid.Natural phospholipid comprises soybean lecithin, Ovum Gallus domesticus Flavus lecithin; Semi-synthetic phospholipid comprises hydrogenated soy phosphatidyl choline (HSPC), hydrogenated yolk lecithin; Synthetic phospholipid comprises DSPC (distearoyl phosphatidylcholine), DPPC (dipalmitoyl phosphatidyl choline), DMPC (dimyristoyl phosphatidyl choline), DLPC (two Laurel phosphatidyl cholines), DSPG (distearyl phosphatidyl glycerol), DPPG (two palmityl phosphatidyl glycerols), DMPG (GLYCEROL,DIMYRISTOYL PHOSPHATIDYL), DLPG (two lauroyl phosphatidyl glycerols), PA (phosphatidic acid), PI (phosphatidylinositols), PS (Phosphatidylserine).Said Emulsion is made up of medicine and oil phase, emulsifying agent, co-emulsifier, the proportion of composing of medicine and oil phase, emulsifying agent, co-emulsifier is: 1: 0.5-500: 1-50: 0-50 (W/W/W), its pH scope is: 4-8 (the medicine indissoluble is separated in this scope), particle size range is 10nm-5000nm.Said oil phase is C
0-C
18Vegetable oil or animal oil (comprising), triglyceride through the vegetable oil after structure of modification and the hydrolysis, as Oleum Cocois, olive oil, soybean oil, safflower oil, seal oil, hot certain herbaceous plants with big flowers acid glyceride (Delios ) (being called medium chain triglycerides MCT); The derivant that also comprises fatty acid is as ethyl oleate.Emulsifying agent comprises one or more mixture in phospholipid, HS15 (Polyethylene Glycol 12-hydroxy stearic acid ester, polyethylene glycol 660 hydroxystearate), vitamin E polyethylene glycol succinic acid ester (TPGS), the Tweens; Co-emulsifier comprises ethanol, glycerol, C
8-C
30Saturated or unsaturated fatty acid, as caproic acid, sad, certain herbaceous plants with big flowers is sour, one or more mixture in lauric acid, Palmic acid, (Asia) oleic acid, linoleic acid, stearic acid, docosahexenoic acid (DHA), cholic acid (pig, goose, ursodesoxycholic acid), dehydrocholic acid and the salt thereof; Said nanoparticle comprises " lipid nanoparticle " and " human albumin's (comprising human serum albumin (HSA), albumin human) nanoparticle ".Wherein " lipid nanoparticle " is made up of medicine and phospholipid substance, proportion of composing is: 1: whether 10-1000 (can change 1 into: 1-1000 embodiment 11) (W/W), also can add other appropriate ingredients as required, as vitamin E, HS15 (Polyethylene Glycol 12-hydroxy stearic acid ester, polyethylene glycol 660 hydroxystearate), vitamin E polyethylene glycol succinic acid ester (TPGS), DSPE-PEG, Poloxamer 407; Its pH scope is: 3-9, particle size range is 5nm-1000nm." human albumin's (comprising human serum albumin (HSA), albumin human) nanoparticle " is made up of medicine and human albumin, and wherein the ratio of Irisquinonum and human albumin, oil is 1: 1-100: 0-10, said oil are C
6-C
18Vegetable oil (comprising), triglyceride through the vegetable oil after structure of modification and the hydrolysis, as Oleum Cocois, olive oil, soybean oil, safflower oil, seal oil, hot certain herbaceous plants with big flowers acid glyceride (Delios ) (being called medium chain triglycerides MCT), its pH scope is: 3-9, particle size range is 5nm-1000nm.Said phospholipid substance comprises that PC (phosphatidylcholine) content forms greater than 40% albumin, and wherein the ratio of Irisquinonum and human albumin, oil is 1: 1~100: 0~10, and said oil is C
6~C
18Vegetable oil (comprising), triglyceride through the vegetable oil after structure of modification and the hydrolysis, as Oleum Cocois, olive oil, soybean oil, safflower oil, seal oil, hot certain herbaceous plants with big flowers acid glyceride (Delios ) (being called medium chain triglycerides MCT), its pH scope is: 3~9, and particle size range is 5nm~1000nm.Said phospholipid substance comprises that PC (phosphatidylcholine) content is greater than 40% natural phospholipid, semi-synthetic phospholipid or synthetic phospholipid.Natural phospholipid comprises soybean lecithin, Ovum Gallus domesticus Flavus lecithin; Semi-synthetic phospholipid comprises hydrogenated soy phosphatidyl choline, hydrogenated yolk lecithin; Synthetic phospholipid comprises DSPC (distearoyl phosphatidylcholine), DPPC (dipalmitoyl phosphatidyl choline), DMPC (dimyristoyl phosphatidyl choline), DLPC (two Laurel phosphatidyl cholines), DSPG (distearyl phosphatidyl glycerol), DPPG (two palmityl phosphatidyl glycerols), DMPG (GLYCEROL,DIMYRISTOYL PHOSPHATIDYL), DLPG (two lauroyl phosphatidyl glycerols), PA (phosphatidic acid), PI (phosphatidylinositols), PS (Phosphatidylserine).Can add antioxidant in the sword-like iris seed preparation of said injectable administration, comprise one or more mixture among Butylated hydroxyanisole (BHA), dibenzylatiooluene (BHT), alpha-tocopherol, α-tocopheryl acetate, alpha-lipoic acid, vitamin C, sodium L-ascorbate-2-phosphate, sulfurous acid (hydrogen) sodium, noble gas (nitrogen, argon), the EDTA (2Na or sodium calcium salt).The freeze drying protectant that said lyophilization injectable powder relates to is: one or more mixture in glucose, lactose, mannitol, sorbitol, xylitol, sucrose, trehalose, dextran, polyvinylpyrrolidone (PVP), glycine, succinylated gelatin, human albumin, the sodium chloride etc.; the content of freeze drying protectant is 2%~20% (W/V, protectant concentration in the preceding solution of lyophilizing).Described injection preparation method, with Emulsion is that example is described as follows: 1) prepare oil phase (medicine phase) in preparing tank: in preparing tank, oil for injection is heated to 20-90 ℃ when medicine (simple non-refuelling), adds emulsifying agent, strong agitation is to dissolving in the time of 20~80 ℃; Be cooled to 20~40 ℃ again, in stirring, add medicine.2) in preparing tank, prepare water: water and glycerol are stirred 5min down at 20~90 ℃, make it complete miscibility.3) in the time of 20~50 ℃, water is added in the oil phase, strong agitation 10~30min forms colostrum.4) colostrum is crossed G
3The funnel sucking filtration is regulated pH value to 4~8.5) cross the homogenizing instrument, the first step is regulated homogenize pressure to 520~600kg/cm
2, second step re-adjustment to 100~140kg/cm
2(or the microjet instrument, the first step is regulated homogenize pressure to 4000-8000psi, and the second step re-adjustment is to 10000-16000psi), form Emulsion.Cross the following microporous filter membrane of 0.8um or 0.8um, packing (add protective agent, carry out lyophilization, or carry out spray drying) promptly gets Emulsion.
Advantage of the present invention is: the mice in vivo test is the result show, prepared preparation infiltration rate of the present invention and degree are better than the commercial preparation far away, blood drug level is higher than the commercial preparation (nanoparticle of the Emulsion of the liposome of embodiment 2, embodiment 7, embodiment 14, its with respect to the bioavailability of commercial preparation all greater than 200%), the time of keeping also is longer than the commercial preparation.The curative effect of anti-mice ehrlich ascites tumor also is better than the commercial preparation.
The specific embodiment:
Detailed component of the present invention is provided by the following example, but protection scope of the present invention not only is confined to this.
Particle size analyzer: use PSS.NICOMP in this experiment
TM380 as the instrument of measuring particle diameter.
Microjet instrument (Microfluidic company, the U.S.), homogenizer etc.
HPLC analyzes: chromatographic column: ODS post; Mobile phase: methanol-water-acetonitrile-ether (65: 25: 20: 20); Detect wavelength: 270nm; Flow velocity: 1mL/ minute.50μl。
Embodiment 1 Irisquinonum liposome
Composition weight (gram)
Irisquinonum 1
Soybean lecithin 5
Ethanol is an amount of
Citrate buffer solution adds to 100
Preparation technology:
Take by weighing Irisquinonum, the soybean lecithin of recipe quantity, behind an amount of dissolve with ethanol, (0.01mol/L, pH4.0), 40 ℃ are stirred aquation down, cross homogenizer (or microjet) (first step adjusting homogenize pressure 520~600kg/cm to add citrate buffer solution
2, second step re-adjustment 100~140kg/cm
2Microjet instrument, the first step are regulated homogenize pressure to 4000-8000psi, and the second step re-adjustment is to 10000-16000psi) get the Irisquinonum liposome, its granularity is 15nm~550nm.The trehalose that gained liposome liquid can add 12% (W/V) carries out lyophilization, gets freeze-dried lipidosome.After the redissolution, its granularity is 10nm~710nm.The gained preparation can oral or injection.
Embodiment 2 Irisquinonum liposomees
Composition weight (gram)
Irisquinonum 1
Soybean lecithin 50
Ethanol is an amount of
Alpha-tocopherol 0.1
Phosphate buffer adds to 1000
Preparation technology:
Take by weighing Irisquinonum, soybean lecithin, the alpha-tocopherol of recipe quantity, behind an amount of dissolve with ethanol, (0.01mol/L, pH5.0), 40 ℃ are stirred aquation down, cross homogenizer (or microjet), first step adjusting homogenize pressure 520kg/cm to add phosphate buffer
2, the second step re-adjustment 100kg/cm
2(or the microjet instrument, the first step is regulated homogenize pressure to 4000psi, and the second step re-adjustment is to 10000psi), get the Irisquinonum liposome, cross the 0.22um microporous filter membrane, its granularity is 25nm~430nm, envelop rate is greater than 90%.The glucose that gained liposome liquid can add the mannitol and 1% (W/V) of 6% (W/V) carries out lyophilization, gets freeze-dried lipidosome, every 5mg Irisquinonum (or vacuum gland).After the redissolution, its granularity is 20nm~710nm.The gained preparation can be oral (can add 0.1% sodium benzoate) or injection.
Embodiment 3 Irisquinonum liposomees
Composition weight (gram)
Irisquinonum 1
Ovum Gallus domesticus Flavus lecithin 20
Cholesterol 1
Alpha-lipoic acid 0.5
Ethanol is an amount of
Acetate buffer adds to 1000
Preparation technology:
Take by weighing Irisquinonum, Ovum Gallus domesticus Flavus lecithin, cholesterol, the alpha-lipoic acid of recipe quantity, behind an amount of dissolve with ethanol, adopt alcohol injection to add phosphate buffer (0.03mol/L, pH6.0) in, 50 ℃ are stirred aquation down, cross homogenizer (or microjet), the first step is regulated homogenize pressure to 600kg/cm
2, the second step re-adjustment is to 100kg/cm
2(or the microjet instrument, the first step is regulated homogenize pressure to 5000psi, and the second step re-adjustment is to 10000psi), getting the Irisquinonum liposome, its granularity is 10nm~820nm, crosses the 0.22um microporous filter membrane, envelop rate is greater than 90%.The lactose that gained liposome liquid can add the sucrose, 5% (W/V) of 10% (W/V) carries out lyophilization, promptly gets freeze-dried lipidosome; Or carry out spray drying, get pro-liposome.The packing inflated with nitrogen gets Liposomal formulation, every 5mg Irisquinonum (or vacuum gland).After the redissolution, its granularity is 20nm~780nm.The gained preparation can be oral (can add 0.1% sodium benzoate, 0.05% ethyl hydroxybenzoate) or injection.
Embodiment 4 Irisquinonum liposomees
Composition weight (gram)
Irisquinonum 1
DSPG 100
Cholesterol 50
Sodium L-ascorbate-2-phosphate 0.2
Ethanol is an amount of
Phosphate buffer adds to 5000
Preparation technology:
Take by weighing Irisquinonum, DSPG, the cholesterol sodium L-ascorbate-2-phosphate of recipe quantity, behind an amount of dissolve with ethanol, adopt alcohol injection to add phosphate buffer (0.03mol/L, pH7.0) in, 50 ℃ are stirred aquation down, cross homogenizer (or microjet), the first step is regulated homogenize pressure to 600kg/cm
2, the second step re-adjustment 140kg/cm
2(or the microjet instrument, the first step is regulated homogenize pressure to 8000psi, and the second step re-adjustment is to 16000psi), get the Irisquinonum liposome, cross the 0.3um microporous filter membrane, its granularity is 20nm~900nm, envelop rate is greater than 80%.The sucrose that gained liposome liquid can add 20% (W/V) carries out lyophilization, promptly gets freeze-dried lipidosome; Or carry out spray drying, get pro-liposome.The packing inflated with nitrogen gets Liposomal formulation, every 10mg Irisquinonum (or vacuum gland).After the redissolution, its granularity is 20nm~800nm.The gained preparation can oral or injection.
Embodiment 5 Irisquinonum liposomees
Composition weight (gram)
Irisquinonum 1
HSPC 10
DMPC 20
Ethanol is an amount of
Water for injection adds to 1000ml
Preparation technology:
Take by weighing Irisquinonum, HSPC, the DMPC of recipe quantity, behind an amount of dissolve with ethanol, add injection 600ml, in the gnotobasis, 50 ℃ are stirred aquation down, get the Irisquinonum liposome, and its granularity is 362nm~5000nm, and envelop rate is greater than 90%.The packing inflated with nitrogen gets Liposomal formulation, and every 5mg contains Irisquinonum (or vacuum gland).
Embodiment 6 Irisquinonum Emulsions
Composition weight (gram)
Irisquinonum 1
Soybean oil 0.5
Phosphatidase 11 0
Oleic acid 0.05
Glycerol 2.4
Water for injection adds to 200ml
Preparation technology:
1) prepare oil phase (medicine phase) in preparing tank: in preparing tank, add (injection) soybean oil, oleic acid (20 ℃), add emulsifying agent phospholipid, strong agitation is to dissolving in the time of 50 ℃; Be cooled to 40 ℃ again, in stirring, add medicine.2) in preparing tank, prepare water: water and glycerol are stirred 5min down at 90 ℃, make it complete miscibility.3) in the time of 50 ℃, water is added in the oil phase, strong agitation 30min forms colostrum.4) colostrum is crossed G
3The funnel sucking filtration.5) cross the homogenizing instrument, the first step is regulated homogenize pressure to 520kg/cm
2, the second step re-adjustment 140kg/cm
2(or the microjet instrument, the first step is regulated homogenize pressure 4000psi, and the second step re-adjustment is to 10000psi), form Emulsion, regulate pH value to 4.Cross the 0.3um microporous filter membrane, packing, inflated with nitrogen, every 1ml (containing medicine 5mg), every 2ml (containing medicine 10mg) or every 10ml (containing medicine 50mg), sterilization promptly gets (injection) Emulsion.Granularity is 10nm~1000nm, particle mean size 152nm.Add 20% (W/V) lactose, carry out lyophilization after the dissolving, promptly get freeze-dried emulsion; Or carry out spray drying, get precursor Emulsion.The packing inflated with nitrogen, every 5mg Irisquinonum.The gained preparation can oral or injection.
Embodiment 7 Irisquinonum Emulsions
Composition weight (kilogram)
Irisquinonum 1
Hot certain herbaceous plants with big flowers acid glyceride 20
HS15 2
Phosphatidase 11 0
Glycerol 12
Water for injection adds to 1000
Preparation technology:
1) prepare oil phase (medicine phase) in preparing tank: in preparing tank, add (injection or oral level) hot certain herbaceous plants with big flowers acid glyceride (50 ℃), add emulsifying agent phospholipid, HS15, strong agitation is to dissolving in the time of 80 ℃; Lower the temperature 30 ℃ again, in stirring, add medicine.2) in preparing tank, prepare water: water and glycerol are stirred 5min down at 90 ℃, make it complete miscibility.3) in the time of 40 ℃, water is added in the oil phase, strong agitation 30min forms colostrum.4) colostrum is crossed G
3The funnel sucking filtration is regulated pH value to 6.5) cross the homogenizing instrument, the first step is regulated homogenize pressure to 450kg/cm
2, the second step re-adjustment is to 120kg/cm
2(or the microjet instrument, the first step is regulated homogenize pressure to 6000psi, the second step re-adjustment 12000psi), form Emulsion.Cross the 0.3um microporous filter membrane, packing, inflated with nitrogen, every 3ml (containing medicine 3mg) or every 6ml (containing medicine 6mg), sterilization promptly gets injectable emulsion.Granularity is 50nm~700nm, particle mean size 178nm.The sucrose that can add 20% (W/V) in the gained Emulsion carries out lyophilization, promptly gets freeze-dried emulsion; Or carry out spray drying, get precursor Emulsion.The packing inflated with nitrogen, every 5mg Irisquinonum.After the redissolution, its granularity is 65nm~960nm.The gained preparation can be oral (can add 0.1% sodium benzoate, 0.05% ethyl hydroxybenzoate, cream flavour) or injection.
Embodiment 8 Irisquinonum Emulsions
Composition weight (gram)
Irisquinonum 1
Oleum Cocois 10
TPGS 10
Glycerol 12
Alpha-tocopherol 1
Water for injection adds to 1000
Preparation technology:
Operation is with embodiment 7, and granularity is 20nm~750nm, particle mean size 89nm.Every 5ml (containing medicine 5mg) or every 10ml (containing medicine 10mg) (applying argon gas).Mannitol, 2% xylitol that can add 8% (W/V) in the gained Emulsion carry out lyophilization, promptly get freeze-dried emulsion; Or carry out spray drying, get precursor Emulsion.The packing inflated with nitrogen, every 5mg Irisquinonum.After the redissolution, its granularity is 15nm~680nm.The gained preparation can oral (0.1% ethyl hydroxybenzoate, 0.05% propylparaben, protein sugar, cocoanut flavour) or injection.
Embodiment 9 Irisquinonum Emulsions
Composition weight (gram)
Irisquinonum 0.1
Hot certain herbaceous plants with big flowers acid glyceride 50
Soybean oil 0.5
TPGS 10
Poloxamer?407 5
Glycerol 2.4
Alpha-lipoic acid 1
Water for injection adds to 200
Preparation technology:
Operation is with embodiment 7, and granularity is 50nm~1060nm.Every 10ml (containing medicine 5mg) (argon).The gained preparation can oral or injection.
Embodiment 10 Irisquinonum Emulsions
Composition weight (kilogram)
Irisquinonum 1
Ethyl oleate 10
Phosphatidase 12
HS15 2
DHA 10
Glycerol 1.2
Alpha-lipoic acid 0.2
Water for injection adds to 200
Preparation technology:
Operation is with embodiment 7, pH8, and the sterile working, granularity is 100nm~5000nm.Every 1ml (containing medicine 5mg) or every 2ml (containing medicine 10mg), (applying argon gas).Add 6% mannitol, 6% xylitol, lyophilizing or spray drying get pressed powder.The gained preparation can oral or injection.
Embodiment 11 Irisquinonum nanoparticles
Composition weight (gram)
Irisquinonum 1
Soybean lecithin 10
HS15 5
Ethanol is an amount of
Alpha-lipoic acid 1
Glycerol 2
Water adds to 1000
Preparation technology:
Take by weighing Irisquinonum, phospholipid, HS15, the alpha-lipoic acid of recipe quantity, place material-compound tank, add ethanol, after 50 ℃ of heating for dissolving, add entry (containing glycerol) and stir, disperse, transfer pH to 4, cross homogenizer (or microjet), the first step is regulated homogenize pressure to 600kg/cm
2, the second step re-adjustment is to 140kg/cm
2(or the microjet instrument, the first step is regulated homogenize pressure to 8000psi, and the second step re-adjustment is to 16000psi), get the Irisquinonum liquid nano, cross 0.22 μ m microporous filter membrane degerming, packing, every 10ml (containing medicine 10mg) (applying argon gas).The mensuration granularity is 5nm~500nm.Add 10% sucrose in the gained liquid, carry out spray drying or lyophilization, get sterilized powder.Granularity after spray drying or the lyophilization gained solid rehydration is: 10nm~1000nm.The gained preparation can oral or injection.
Embodiment 12 Irisquinonum nanoparticles
Composition weight (gram)
Irisquinonum 0.1
Ovum Gallus domesticus Flavus lecithin 100
Hydrogenated soy phosphatidyl choline 1
Ethanol is an amount of
Vitamin E 1
Glycerol 30
Mannitol 50
Water adds to 1000
Preparation technology:
Take by weighing Irisquinonum, phospholipid, vitamin E, the hydrogenated soy phosphatidyl choline of recipe quantity, place material-compound tank, add ethanol, after 60 ℃ of heating for dissolving, standby.Take by weighing mannitol, the glycerol of recipe quantity in addition, behind the adding water dissolution, mix with above-mentioned Irisquinonum phospholipid solution, stir aquation, transfer pH to 6, cross homogenizer (or microjet), the first step is regulated homogenize pressure to 500kg/cm
2, the second step re-adjustment is to 120kg/cm
2(or the microjet instrument, the first step is regulated homogenize pressure to 6000psi, and the second step re-adjustment is to 13000psi), get the Irisquinonum liquid nano.Its granularity is 5nm~300nm.Cross 0.22 μ m microporous filter membrane degerming, packing, inflated with nitrogen.Gained liquid carries out spray drying or lyophilization, gets sterilized powder.Granularity after the rehydration is: 10nm~400nm.The gained preparation can oral or injection.
Embodiment 13 Irisquinonum nanoparticles
Composition weight (gram)
Irisquinonum 0.1
The human albumin 3
Dichloromethane is an amount of
Preparation technology:
Take by weighing the Irisquinonum of recipe quantity,, make the solution of 100mg/ml with the dichloromethane dissolving, standby.Get commercially available human albumin (25%) and be diluted to 5% solution, and be 5.5 with hydrochloric acid adjusting pH value with water for injection, standby.Under 0 ℃ the Irisquinonum dichloromethane solution is mixed with human albumin's solution, cross homogenizer (or microjet), the first step is regulated homogenize pressure to 600kg/cm
2, the second step re-adjustment is to 140kg/cm
2(or the microjet instrument, the first step is regulated homogenize pressure to 6000psi, and the second step re-adjustment is to 36000psi), get the Irisquinonum liquid nano.Its granularity is 5nm~550nm.Cross 0.22 μ m microporous filter membrane degerming, packing, lyophilization gets sterilized powder.Particle mean size after the rehydration (normal saline or sterilized water for injection) is: 170nm.Can be with different ratios, different acid replaces hydrochloric acid as citric acid, phosphoric acid, tartaric acid, acetic acid, and pH value is 3~8, can obtain similar results.The gained preparation can oral or injection.
Embodiment 14 Irisquinonum nanoparticles
Composition weight (gram)
Irisquinonum 1
Ovum Gallus domesticus Flavus lecithin 30
Ethanol is an amount of
Vitamin E 1
Deoxycholic acid 10
Mannitol 50
Glucose 10
Water adds to 1000
Preparation technology:
Take by weighing Irisquinonum, phospholipid, vitamin E, the deoxycholic acid of recipe quantity, place material-compound tank, add ethanol, after 50 ℃ of heating for dissolving, standby.Take by weighing mannitol, the glucose of recipe quantity in addition, behind the adding water dissolution, mix with above-mentioned Irisquinonum phospholipid solution, stir aquation, transfer pH to 8, cross homogenizer (or microjet), the first step is regulated homogenize pressure to 600kg/cm
2, the second step re-adjustment is to 140kg/cm
2(or the microjet instrument, the first step is regulated homogenize pressure to 7000psi, and the second step re-adjustment is to 26000psi), get the Irisquinonum liquid nano.Its granularity is 5nm~500nm.Cross 0.22 μ m microporous filter membrane degerming, packing, every 5ml (contains medicine (inflated with nitrogen).Gained liquid carries out spray drying or lyophilization, gets sterilized powder.Granularity after the rehydration is: 10nm~500nm.The gained preparation can oral or injection.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510046524 CN1706371B (en) | 2005-05-27 | 2005-05-27 | Efficient sword-like iris seed preparation and its preparation process |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510046524 CN1706371B (en) | 2005-05-27 | 2005-05-27 | Efficient sword-like iris seed preparation and its preparation process |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1706371A true CN1706371A (en) | 2005-12-14 |
CN1706371B CN1706371B (en) | 2010-11-10 |
Family
ID=35580605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200510046524 Expired - Fee Related CN1706371B (en) | 2005-05-27 | 2005-05-27 | Efficient sword-like iris seed preparation and its preparation process |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1706371B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102802605A (en) * | 2009-04-30 | 2012-11-28 | 雅培制药有限公司 | Stable lipid formulations of apoptosis promoters |
CN103200932A (en) * | 2010-06-23 | 2013-07-10 | 布莱特赛德创新有限公司 | Lecithin carrier vesicles and methods of making the same |
CN103800910A (en) * | 2012-11-14 | 2014-05-21 | 沈阳药科大学 | Composition capable of eliminating clouding phenomenon of Tween surfactants |
US8927009B2 (en) | 2009-12-22 | 2015-01-06 | Abbvie Inc. | ABT-263 capsule |
US9642796B2 (en) | 2009-06-08 | 2017-05-09 | Abbvie Inc. | Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor |
CN113041222A (en) * | 2021-03-23 | 2021-06-29 | 北京诺康达医药科技股份有限公司 | Injection emulsion and preparation method thereof |
US11369599B2 (en) | 2010-10-29 | 2022-06-28 | Abbvie Inc. | Melt-extruded solid dispersions containing an apoptosis-inducing agent |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100377712C (en) * | 2002-11-28 | 2008-04-02 | 沈阳药科大学 | Cucurbitacin Liposome Prescription and Its Preparation |
-
2005
- 2005-05-27 CN CN 200510046524 patent/CN1706371B/en not_active Expired - Fee Related
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102802605A (en) * | 2009-04-30 | 2012-11-28 | 雅培制药有限公司 | Stable lipid formulations of apoptosis promoters |
US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
CN102802605B (en) * | 2009-04-30 | 2015-08-12 | Abbvie公司 | Stable lipid formulations of apoptosis promoters |
US9642796B2 (en) | 2009-06-08 | 2017-05-09 | Abbvie Inc. | Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor |
US8927009B2 (en) | 2009-12-22 | 2015-01-06 | Abbvie Inc. | ABT-263 capsule |
TWI508729B (en) * | 2009-12-22 | 2015-11-21 | Abbvie Inc | Abt-263 capsule |
CN103200932A (en) * | 2010-06-23 | 2013-07-10 | 布莱特赛德创新有限公司 | Lecithin carrier vesicles and methods of making the same |
US11369599B2 (en) | 2010-10-29 | 2022-06-28 | Abbvie Inc. | Melt-extruded solid dispersions containing an apoptosis-inducing agent |
CN103800910A (en) * | 2012-11-14 | 2014-05-21 | 沈阳药科大学 | Composition capable of eliminating clouding phenomenon of Tween surfactants |
CN103800910B (en) * | 2012-11-14 | 2015-12-09 | 沈阳药科大学 | The composition that can eliminate the phenomenon of Tween surfactants |
CN113041222A (en) * | 2021-03-23 | 2021-06-29 | 北京诺康达医药科技股份有限公司 | Injection emulsion and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1706371B (en) | 2010-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2144610B1 (en) | Melatonin tablet and methods of preparation and use | |
US6441050B1 (en) | Palatable oral coenzyme Q liquid | |
CN1620283A (en) | Preparation of dispersions of slightly or poorly soluble active ingredients | |
CN1042080A (en) | Pharmaceutical carrier | |
JP3486778B2 (en) | Alzheimer's disease preventive / treatment agent | |
CN1857222A (en) | Submicron docetaxel emulsion for intravenous injection and its preparing process | |
AU2019363244B2 (en) | Pharmaceutical formulation | |
JP2014133764A (en) | Taxol submicroemulsion with steroidal compound as intermediate carrier | |
PT2345426E (en) | Composite organic compound powder for medical use, method for producing same and suspension of same | |
CN1525850A (en) | Coenzyme Q10 containing microemulsion preconcentrates and microemulsions | |
CN1596882A (en) | Vitamin K1 emulsion and its freeze-dried emulsion and preparation method | |
WO2021196659A1 (en) | Glycosyl polyether compound liposome, preparation method therefor and medicine thereof | |
CN1706371A (en) | A kind of efficient irinatin preparation and preparation method thereof | |
WO2022061870A1 (en) | Vitamin k2 microcapsule, preparation method therefor, and application thereof in preparation of medicine for preventing and treating cardiovascular and cerebrovascular diseases | |
CN102552134A (en) | Fat emulsion containing vitamin K1 | |
CN102552135A (en) | Method for preparing vitamin K1 emulsion, and vitamin K1 emulsion | |
CN1739525A (en) | A Novel Polyethylene Glycol Derivatized Phospholipid Encapsulated Nanoparticle Drug Delivery System of Prostaglandin E1 | |
TW202103726A (en) | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability | |
CN1561970A (en) | Fat soluble vitamin freeze-drying emulsion and its preparing method | |
WO2023126026A2 (en) | Epa-ee lipid nanocomposite, formulation thereof, preparation method therefor, and application thereof | |
CN106137957A (en) | A kind of oleanolic acid type saponin fat microemulsion and preparation method thereof | |
CN1973826A (en) | Injection containing lipoid microsphere of etoposide and its prepn process | |
CN1698620A (en) | A filter-sterilizable cucurbitacin emulsion and preparation method thereof | |
CN1827632A (en) | Zidovudine palmitate raw material refining method and preparation | |
CN1562014A (en) | V emulsion nicotinate for injection and its preparing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101110 Termination date: 20150527 |
|
EXPY | Termination of patent right or utility model |